From: Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death
Treatment
IC50
Selectivity Index (SI)
HepG2
WI-38
Amygdalin (mg/ml)
5.21 ± 0.09
141.25 ± 0.23
27.1
Sorafenib (µM)
2.21 ± 0.06
0.59 ± 0.002
0.27